Throughout our company’s history, we combined scientific innovation with operational excellence to pursue breakthroughs that improve patient outcomes. This work resulted in a broad portfolio of investigational and approved medicines, including the development of AYVAKIT®/AYVAKYT® (avapritinib) for patients with systemic mastocytosis in the U.S. and Europe, as well as programs in mast cell diseases and solid tumors.

In 2025, we announced our acquisition by Sanofi to accelerate our shared mission to bring life-changing medicines to patients around the world.